Literature DB >> 24607203

Biopharmaceutics classification of puerarin and comparison of perfusion approaches in rats.

Hewei Li1, Ling Dong2, Yang Liu3, Guopeng Wang4, Gang Wang4, Yanjiang Qiao3.   

Abstract

The present study was conducted to characterize the biopharmaceutics classification system (BCS) category of puerarin in terms of intrinsic dissolution rate (IDR) and rat intestinal permeability and to investigate the poor intestinal absorption probably related to the drug metabolism in the gut wall of rats. Equilibrium solubility of puerarin was determined in various phosphate buffers and water, and IDR was estimated by measuring the dissolution of a non-disintegrating compact. Intestinal permeability (Peff and Pblood) of puerarin was determined using the technology of in situ single-pass intestinal perfusion (SPIP) and intestinal perfusion with venous sampling (IPVS) in fasted rats. Metabolism of puerarin in intestinal tissue was tested by S9 incubation in vitro. The aqueous solubility of puerarin in phosphate buffers and water was good with a maximum solubility of 7.56 mg/mL at pH 7.4. Obtained IDR values of puerarin were in the range of 0.360-1.088 mg/min/cm(2), with maximum and minimum IDR value of pH 7.4 and pH 4.0, respectively. The Peff was 1.252 × 10(-5)cm/s determined by SPIP and the Pblood was 0.068×10(-5)cm/s by IPVS in jejunum at puerarin 80 μg/mL. The metabolism rate of puerarin determined by the intestinal S9 fraction indicated that the gut wall metabolism of puerarin is one cause of poor absorption. According to the proposed classification of drugs and the results obtained from equilibrium solubility, IDR, Peff and Pblood, it is concluded that puerarin could be categorized IV drug of the BCS based on its low solubility and low intestinal permeability values.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Biopharmaceutical classification system; Gut wall metabolism; Intrinsic Dissolution rate; Puerarin; S9

Mesh:

Substances:

Year:  2014        PMID: 24607203     DOI: 10.1016/j.ijpharm.2014.03.014

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  13 in total

1.  Puerarin-7-O-glucuronide, a water-soluble puerarin metabolite, prevents angiotensin II-induced cardiomyocyte hypertrophy by reducing oxidative stress.

Authors:  Ning Hou; Bin Cai; Cai-Wen Ou; Zhen-Hui Zhang; Xia-Wen Liu; Mu Yuan; Gan-Jian Zhao; Shi-Ming Liu; Long-Gen Xiong; Jian-Dong Luo; Cheng-Feng Luo; Min-Sheng Chen
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-02-16       Impact factor: 3.000

2.  Biocatalytical Acyl-Modification of Puerarin: Shape Gut Microbiota Profile and Improve Short Chain Fatty Acids Production in Rats.

Authors:  Lan Mo; Guang-Lei Zhao; Xiao-Feng Li; Ning He; Xing-Long Xiao; Hai-Xia Xu; Yi-Gang Yu
Journal:  Plant Foods Hum Nutr       Date:  2021-11-25       Impact factor: 3.921

3.  Neuroprotective Mechanisms of Puerarin in Central Nervous System Diseases: Update.

Authors:  Chao-Chao Yu; Yan-Jun Du; Jin Li; Yi Li; Li Wang; Li-Hong Kong; Ying-Wen Zhang
Journal:  Aging Dis       Date:  2022-07-11       Impact factor: 9.968

4.  Puerarin inhibits proliferation and induces apoptosis in human glioblastoma cell lines.

Authors:  Ji-An Yang; Ji-Qiang Li; Ling-Min Shao; Qian Yang; Bao-Hui Liu; Ting-Feng Wu; Peng Wu; Wei Yi; Qian-Xue Chen
Journal:  Int J Clin Exp Med       Date:  2015-06-15

5.  Establishment of a Novel In Situ Rat Model for Direct Measuring of Intestinal Drug Absorption: Confirmation of Inhibitory Effects of Daijokito on the Absorption of Ranitidine.

Authors:  Weibin Qian; Junichi Hasegawa; Jie Yang; Yusuke Endo; Junichiro Miake
Journal:  Yonago Acta Med       Date:  2018-12-27       Impact factor: 1.641

6.  Enhancing both oral bioavailability and brain penetration of puerarin using borneol in combination with preparation technologies.

Authors:  Tao Yi; Dandan Tang; Fan Wang; Jiqiong Zhang; Jiao Zhang; Jirui Wang; Xiaoyu Xu; Jifen Zhang
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

Review 7.  Self-Emulsifying Granules and Pellets: Composition and Formation Mechanisms for Instant or Controlled Release.

Authors:  Ioannis Nikolakakis; Ioannis Partheniadis
Journal:  Pharmaceutics       Date:  2017-11-03       Impact factor: 6.321

8.  A Novel Microspheres Formulation of Puerarin: Pharmacokinetics Study and In Vivo Pharmacodynamics Evaluations.

Authors:  Xiao Song; Xihui Bai; Shiyu Liu; Linjuan Dong; Hui Deng; Changli Wang
Journal:  Evid Based Complement Alternat Med       Date:  2016-12-29       Impact factor: 2.629

9.  Absolute oral bioavailability and disposition kinetics of puerarin in female rats.

Authors:  Tosapol Anukunwithaya; Pilaslak Poo; Natthaphon Hunsakunachai; Ratchanee Rodsiri; Suchinda Malaivijitnond; Phisit Khemawoot
Journal:  BMC Pharmacol Toxicol       Date:  2018-05-25       Impact factor: 2.483

10.  Puerarin inhibits bladder cancer cell proliferation through the mTOR/p70S6K signaling pathway.

Authors:  Kehua Jiang; Hongbo Chen; Kun Tang; Wei Guan; Hui Zhou; Xiaolin Guo; Zhiqiang Chen; Zhangqun Ye; Hua Xu
Journal:  Oncol Lett       Date:  2017-10-31       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.